A BST RACT : Background: Gastrointestinal symptoms are common in Parkinson's disease and frequently precede the development of motor impairments. Intestinal inflammation has been proposed as a driver of disease pathology, and evaluation of inflammatory mediators in stool could possibly identify valuable early-stage biomarkers. We measured immune-and angiogenesis-related proteins in human stool to examine inflammatory profiles associated with Parkinson's disease. Methods: Stool samples and subjects' self-reported metadata were obtained from 156 individuals with Parkinson's disease and 110 without, including spouse and nonhousehold controls. Metadata were probed for disease-associated differences, and levels of 37 immune and angiogenesis factors in stool homogenates were measured by multiplexed immunoassay and compared across experimental groups. Results: Parkinson's disease patients reported greater incidence of intestinal disease and digestive problems than controls. Direct comparison of levels of stool analytes in patients and controls revealed elevated vascular endothelial growth factor receptor 1, interleukin-1a, and CXCL8 in patients' stool. Paired comparison of patients and spouses suggested higher levels of multiple factors in patients, but this was complicated by sex differences. Sex, body mass index, a history of smoking, and use of probiotics were found to strongly influence levels of stool analytes. Multivariate analysis accounting for these and other potential confounders confirmed elevated levels of interleukin-1a and CXCL8 and also revealed increased interleukin-1b and C-reactive protein in stool in Parkinson's disease. These differences were not dependent on subject age or disease duration. Parkinson's disease (PD) is currently defined by motor impairments such as resting tremor, bradykinesia, rigidity, and gait disturbance, but nonmotor features including cognitive impairment, hyposmia, anxiety, depression, sleep disturbances, and, prominently, gastrointestinal (GI) dysfunction have been gaining increasing attention and have a profound impact on quality of life. Constipation is reported by approximately 50% of PD patients 1 and can be detected by objective measures in nearly 80%. 2 It frequently precedes the onset of motor symptoms by more than 15 years. 3 Pathological abnormalities including the PD-related aggregation of a-synuclein (aSYN) have been identified in intestinal biopsies from PD patients 4 and even in subjects in the premotor phase of disease, 5, 6 although consensus on the best interpretation of these results has not been reached (reviewed in reference 7). PD patients also exhibit significant differences in gut bacterial populations [8] [9] [10] [11] [12] [13] [14] [15] [16] and increased intestinal permeability compared with individuals without PD. 17, 18 With accumulating evidence that GI symptoms are present from the earliest stages of PD, it has been proposed that PD pathology may originate in the gut and later spread to the central nervous system (CNS). Immune activity may advance this progression, as intestinal inflammation can promote systemic and also CNS inflammation, 19, 20 which contributes to PD-related neurodegeneration. 21 Intestinal symptoms observed in PD are consistent with conditions of inflammation. Constipation in PD patients is attributed to slow intestinal transit time, 22 ,23 a symptom that is also frequently observed in other conditions involving chronic GI inflammation such as inflammatory bowel disease (IBD) 24 and obesity. 25 Mechanistically, this condition has been linked to intestinal immune activation 26 and to intestinal dysbiosis, which is another hallmark of disorders involving gut inflammation. 24, 27 Immune activation promotes increased aSYN expression and aggregation, 17, 28, 29 and aSYN in turn stimulates proinflammatory immune responses. 28, 30 In keeping with the well-known connections between inflammatory stimuli and impairment of gut barrier function, 17, 31 intestinal permeability in PD correlates with levels of aSYN as well as indicators of oxidative stress. 18 In addition, recent studies have reported significant coincidence of IBD or irritable bowel syndrome and PD. [32] [33] [34] One study reported the most direct confirmation of intestinal inflammation in PD, finding increases in mRNA transcripts encoding 4 proinflammatory cytokines (tumor necrosis factor, interferon gamma, interleukin-6, and interleukin-1b) as well as 3 glial markers in colonic biopsies of PD patients compared with age-matched healthy controls. 35 Given the accumulation of evidence suggesting that pronounced GI dysfunction and dysbiosis occur in PD, we conducted an extensive analysis of immune and angiogenesis factors in stool to assess the GI inflammatory state in PD patients, their healthy spouses, and unrelated healthy control subjects. We also evaluated the prevalence of certain PD-associated nonmotor symptoms in our subject cohort and assessed how these and other physiological and lifestyle factors influenced levels of stool analytes.
Methods Subjects
A subset of the NeuroGenetics Research Consortium subjects from Atlanta, Georgia, Albany, New York, and Seattle, Washington, were invited to participate (recontacted based on prior institutional review boardapproved consents). These included most of the subjects evaluated for stool microbiota composition described by Hill-Burns et al, 14 excluding those for whom stool samples were of insufficient quantity for this analysis. Of 266 subjects, 156 had been diagnosed with PD by a movement disorder specialist (PD patients), and 110 reported no diagnosis of PD (controls). Within the control group, 49 subjects were spouses of PD patients (household controls), 39 of whom had a spouse participating in this study, and 61 were not known to live with anyone diagnosed with PD (nonhousehold controls). We evaluated whether any significant differences existed between household and nonhousehold control groups in levels of stool analytes (Supplemental Table 1 ) or in various relevant metadata factors (Supplemental Table 2 ), and finding none, we combined these groups for all analyses except a paired comparison of PD patients and their respective spouses. More than 99% of subjects described their race as "white." Ages of participants ranged from 36 to 94 years; mean age of control subjects was 70.8 years (standard deviation, 8.8 years), and mean age of PD subjects was 68.3 years (standard deviation, 8.8 years). A strong male sex bias was observed in PD subjects, with 112 men and 44 women. Accordingly, the opposite sex bias was observed in household controls, with 36 women and 13 men. Nonhousehold controls consisted of 35 men and 26 women. In addition to providing a stool sample, subjects completed a questionnaire on demographics, health problems, medications, and dietary practices. 
Processing of Stool

Multiplexed immunoassays
Immune factor levels were measured in 40 lL of undiluted stool homogenates using the V-PLEX Neuroinflammation Panel 1 (human) Kit (Meso Scale Discovery, Rockville, MD) according to the manufacturer's protocol. This kit is divided into 5 panels of analytes grouped into the physiological categories "Angiogenesis," "Chemokine," "Cytokine," "Proinflammatory," and "Vascular Injury." Analytes measured were: vascular endothelial growth factor receptor 1 (Flt1), placental growth factor (PIGF), tyrosine kinase 2 (Tie- Analyte levels were measured on the Meso Scale Discovery (MSD) QuickPlex instrument and evaluated on the MSD software platform. Values were normalized to total protein measured in each sample by a Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL) according to the manufacturer's protocol.
Statistical Analysis
Chi-square tests (2-tailed) were used to assess relationships between disease status (PD patients/controls) and discrete-valued (e.g., yes/no) responses to various health-related questions. The t test was used to compare stool analyte levels between PD patients and controls, and the Wilcoxon rank sum test was used to compare stool analyte levels between men and women (t test deemed inappropriate because of data skew). General linear models (GLMs) were used to investigate relationships between disease status and metadata factors. Multivariate analysis was performed using multiple regression GLM with multiple imputation (5) with the following potential confounders or effect modifiers: age, sex, geographic location, antibiotic use in the three months prior to stool collection, use of anti-inflammatory drugs which in these subjects included non-steroidal anti-inflammatory drugs or prednisone at least thrice a week (included automatically); body mass index (BMI), smoked at least 100 cigarettes in lifetime, current probiotic use including probiotic supplements or yogurt with live culture (included due to strong effects on stool analyte levels); birth by Caesarean section, digestive problems on the day of stool collection, diarrhea in the three months prior to stool collection, constipation in the three months prior to stool collection, coffee consumption, and alcohol consumption (included because incidence differed significantly between PD patients and controls). Unless otherwise specified, analyses were conducted using PROC GLM and PROC MIXED in SAS/STAT software v9.3 for PC (SAS/STAT 9.3 User's Guide; SAS Institute Inc., Cary, NC).
Results
Increased Incidence of Psychological and Gastrointestinal Symptoms in PD Patients and Decreased Coffee and Alcohol Consumption
As expected, PD patients in this study reported increased incidence of anxiety (11 controls Table 1 ). There was no difference in subjects' reports of ulcers (Supplemental Table 3 ). More than 60% of PD patients who responded to the question reported experiencing digestive problems in the 3 months prior to stool collection, significantly more than controls ( Among our subjects, there was a significant association between reported coffee consumption and disease status (X 2 5 11.61, P 5 0.0205), with controls reporting greater coffee intake (median, 1-2 cups a day) than PD patients (median, 2-6 cups a week); see Table 1 ). No differences were found between PD patients and controls with regard to smoking history, use of antiinflammatory drugs, antibiotics, or probiotics. There were also no significant dietary differences, although a trend of reduced consumption of vegetables/fruits (X 2 5 5.365, P 5 0.0684) and nuts (X 2 5 7.353, P 5 0.0614) among PD patients was present (Supplemental Table 3 ).
Significantly Higher Levels of Select Stool Analytes in PD Patients
We first performed a direct comparison of immuneand angiogenesis-related analyte levels in the stool samples from PD patients and controls. Mean levels of 34 of 37 factors were higher in patients than controls, but 3, Flt1, IL-1a, and CXCL8, met the threshold for significance (P < 0.05; Table 2 ).
To better account for the effects of subject environment on stool analyte levels, we performed a paired 
comparison of PD patients and their respective non-PD spouses. When all PD patients were compared with all household controls by paired t test, there were no significant differences in immune or angiogenesis factor levels. When patient-spouse pairs were separated by patient sex, however, a different pattern emerged. Male PD patients still exhibited no significant differences compared with their female spouses, but female PD patients had higher levels of 11 cytokines, chemokines, and angiogenesis factors compared with male spouses (Table 3) .
Sex Significantly Impacts Stool Analyte Levels
The household control comparison suggested that subject sex greatly impacted immune and angiogenesis factor levels in stool. Indeed, when analyte concentrations of female and male subjects were compared, women exhibited significantly higher levels of 21 of 37 factors (Supplemental Table 4 ). The relationships between sex and disease status for each analyte were largely consistent, but 3 factors, PIGF, CXCL10 (IP-10), and CCL2 (MCP-1), were found at higher concentrations in female PD patients compared with female controls, whereas no differences were found between male patients and controls (Supplemental Fig. 1 ).
BMI, Smoking History, and Probiotic Usage Strongly Influence Stool Analyte Levels
Other metadata variables also influenced stool analyte levels. Nine chemokines and angiogenesis factors Mean protein levels (pg/mg total protein) with standard deviations (SD) in stool homogenates. n, number of measurements for each subject group. Gray shading indicates significant (P < 0.05) difference between patients and controls by t test.
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decreased significantly with increasing subject BMI (Supplemental Fig. 2) . Subjects who reported smoking at least 100 cigarettes in their lives (5 packs) had significantly lower levels of 8 different cytokines and vascular factors in stool (Supplemental Fig. 3 ), regardless of disease status. One classically proinflammatory cytokine, IL-6, was significantly reduced with increasing coffee consumption (Supplemental Fig. 4 ). Consumption of probiotics or probiotic yogurt was associated with significantly higher levels of 3 analytes, TARC (CCL17), IL-7, and MIP-1b, regardless of disease status (Supplemental Fig. 5a ), but an additional 8 factors were significantly elevated only in PD patients taking probiotics (Supplemental Fig. 5b ).
Most of the analytes affected by probiotic use were chemokines.
PD-Associated Stool Inflammatory Profile Emerges When Other Factors Are Accounted for
Given the profound impact of numerous metadata factors on stool analyte levels, we decided to more specifically evaluate PD-associated inflammatory signatures using a multivariate GLM approach, adjusting for 13 metadata parameters. In this analysis, PD disease status was significantly (P < 0.05) associated with elevated levels of IL-1a, IL-1b, CXCL8, and Mean difference (patient -control) between analyte levels (pg/mg total protein) with standard deviations N 5 number of measurements for each subject group Gray shading indicates significant (p<0.05) difference between patients and household controls by paired t-test
Elevations of Flt1 and PIGF were also trending (P 5 0.0541; Table 4 ).
PD-Associated GI Inflammation Does Not Emerge Only in Advanced Disease
Alterations in immune activity occur with aging, 36 and age is the primary risk factor for development of PD. In addition, whether intestinal inflammation and dysfunction represent an independent facet of PD pathology or simply a response to increasing neurodegeneration remains unclear. To explore these potential relationships, we evaluated the effects of subject age and PD duration on the levels of immune and angiogenesis factors. A GLM regression of PD duration (age at time of stool collection minus age of PD onset) versus stool analyte levels revealed no significant association for any analyte (Supplemental Table 5 ). Mean levels of immune and angiogenesis factors remained consistent from recently diagnosed subjects to individuals who had lived with PD for more than 30 years. A GLM analysis evaluating the effects of subject age and disease status on stool analyte levels identified significant decreases in VEGF-C and IL-6 with increasing age, regardless of disease status (Fig. 1 ). Significant differences in the relationships between age and analyte levels for PD patients and controls were identified for MCP-1, TNF, IL-10, and IL-4. Levels of these factors trended toward a decrease with age in PD patients but remained relatively constant with age in controls (Fig. 1) . Although not significant, this same pattern was observed for the majority of analytes measured.
Discussion
PD patients in this study reported the increased incidence of psychiatric and GI symptoms that is typical Gray shading indicates significant (P < 0.05) association with PD status parameter by multivariate GLM, multiple imputation 5 5.
of PD. Measurements of stool immune factors indicated that gastrointestinal inflammation was present in these PD patients. This supports and expands on previous reports of PD-associated dysbiosis, GI dysfunction, and colonic inflammation. When stool analyte levels were directly compared in PD patients and controls, Flt1, IL-1a, and CXCL8 were found to be significantly elevated. PD-associated increases in CXCL8 and IL-1a persisted after adjusting for 13 potential confounders or effect modifiers. CXCL8 is a highly proinflammatory molecule with neutrophil chemoattractant and angiogenic properties. 37 IL-1a is a potent initiator of GI inflammation that triggers recruitment of myeloid cells and their production of additional proinflammatory mediators such as IL1b. 38 Production of IL-1a and IL-1b are induced in inflammation in part through activity of the transcription factor NF-jB, and in an amplification loop, they also stimulate NF-jB activity. 38 In fact, all the inflammatory factors identified in the multivariate analysis as elevated in PD patients -CXCL8, IL-1a, IL-1b, and CRP -are targets for NF-jB transcriptional activity, [39] [40] [41] and like IL-1 cytokines, CRP also promotes NF-jB activity. 42 Our results suggest that this immune signaling pathway may be dysregulated in PD, leading to excessive inflammation.
In the multivariate analysis, elevations in angiogenesis-promoting Flt1 (VEGF receptor 1) and PIGF in stool from PD patients were trending (P 5 0.0541) but not significant. Inflammation and angiogenesis are closely linked 43 and frequently coregulated, for example, by NFjB. 44 Increased proangiogenic factors including VEGF and PIGF have been reported in cerebrospinal fluid from PD patients, and it has been suggested that this promotes the blood-brain barrier dysfunction that has been documented in PD. 45, 46 Further investigation will be needed to determine whether consistent increases in angiogenic factors are present in the intestine in PD patients and how these might contribute to GI pathology.
That disease-associated patterns in immune factor levels did not change with PD duration suggests that FIG. 1. PD patients and controls differ in associations between subject age and levels of stool analytes. Levels (pg/mg) of analytes in stool homogenates from PD patients (blue) and controls (red) as a function of subject age. Significant (P < 0.05) effects of age, disease status, and interactions between the variables by generalized linear model regression.
intestinal inflammation is not exclusively present in advanced disease. PD-associated increases in stool analytes were also not explained by advanced subject age, as, if anything, levels of most analytes trended toward a decrease with age in PD patients. These findings support the hypothesis that intestinal inflammation is an early manifestation of PD that could contribute to the development of neuropathology rather than an effect arising in response to extensive gastrointestinal neurodegeneration. Direct comparison of levels of stool immune and angiogenesis mediators in PD patients and controls was complicated by other variables. For instance, women were found to have significantly higher levels of most analytes measured compared with men. However, the minimal number of significant sex-disease status interactions suggests that there is little sex difference in the nature of the impact that PD has on the gut immune environment. Higher levels of immune factors in stool from female subjects, though, could possibly contribute to differences in the severity of symptoms in PD. 47, 48 Subject sex also influenced the paired comparison of PD patients with their non-PD spouses, with no differences found between male patients and their female spouses, but significantly elevated levels of 11 cytokines, chemokines, and angiogenesis factors in female patients compared with their male spouses. If there were no differences in levels of stool immune and angiogenesis factors between patients and controls, then women should have exhibited significantly higher levels of many analytes regardless of disease status. Instead, only female PD patients exhibited significant elevations compared with their partners, whereas the levels of stool cytokines, chemokines, and angiogenesis factors in men with PD resembled those of their female spouses. This supports a disease-associated increase in numerous immune and angiogenesis mediators that persists in a shared environment.
We also observed several interesting patterns in lifestyle factors that can alter stool immune and angiogenesis factor levels. Although no significant differences in diet between PD patients and controls were reported, the trending reductions in fruit and vegetable and nut consumption in PD patients may warrant further investigation, particularly as the immunomodulatory and neuroprotective potential of these foods in the context of neurodegenerative disease is beginning to emerge. 49, 50 The inverse correlations between BMI and certain stool analyte levels identified in this study may also merit further inquiry. Although increased levels of immune and angiogenesis factors have been reported in serum and adipose tissue of overweight and obese subjects, 51, 52 reductions in serum bFGF and Flt-1 with increasing BMI, such as we observed in stool, have been found. 53, 54 Furthermore, although increased fecal calprotectin in obese subjects suggests intestinal inflammation, 55, 56 the relationship between BMI and levels of other immune and angiogenesis mediators in stool has not been explored, and our results suggest that it is complex.
Coffee and alcohol consumption and smoking are all reportedly reduced in PD patients, [57] [58] [59] [60] [61] but whether these findings indicate protective effects of these practices, disease-associated suppression of psychological reward mechanisms, 59 or simply reduced fluid intake because of dysphagia in advanced disease 62 remains undetermined. We observed reduced current coffee intake in our cohort of PD patients as well as reduced current alcohol consumption, in agreement with previous reports. Although coffee and caffeine are known to have potent neuroprotective and anti-inflammatory properties, 57 this study found only a minimal effect of alcohol and coffee consumption on levels of stool immune mediators, with coffee intake inversely associated with IL-6 levels. We found no differences between PD patients and controls in smoking history, but we did observe that having smoked at least 100 cigarettes reduced levels of multiple immune factors in stool. Although cigarette smoke may have numerous deleterious effects systemically and in the gut, [63] [64] [65] nicotine is known to have anti-inflammatory effects mediated by nicotinic acetylcholine receptor signaling and resulting in, among other effects, inhibition of NFjB. 66 Our results indicate that this immunomodulatory activity is prominent in the human gut. Interestingly, the smokingassociated differences we observed persisted even though more than 92% of respondents in this study who reported having smoked were not current smokers and had been nonsmokers for an average of 36.6 years. This suggests that the modulation of intestinal immune function mediated by smoking may be at least semipermanent, perhaps aided by lasting alterations in the microbiome 59 and by epigenetic modification. 67 The higher levels of chemokines and other inflammatory factors associated with probiotic use, especially in PD patients, could have several explanations. Probiotics are thought to stimulate mucosal immune activity, and they may increase the production of chemokines that recruit primarily tolerogenic cell types. We also noted, however, that nearly 60% of controls and 80% of PD patients who reported using probiotics also reported experiencing digestive problems, so it is possible that the elevated levels of immune factors could result primarily from chronic GI problems rather than probiotics taken for their alleviation. A few studies have reported that the use of probiotics can ameliorate constipation in PD patients 68, 69 ; trials measuring biochemical as well as clinical responses to probiotics may clarify whether these are truly a beneficial treatment for individuals with PD. Furthermore,
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the reciprocal interactions between specific intestinal bacteria, whether transient probiotics or resident commensals, and intestinal immune responses in PD remain to be elucidated and will likely provide greater insight into mechanisms of disease pathology than studies of either factor in isolation. Our study also corroborates the few reports [32] [33] [34] of associations between PD and intestinal disease, with significantly more PD patients than controls in our cohort reporting a history of inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, and/ or colitis. The mechanisms responsible for this epidemiological overlap have not been determined. There may be shared genetic predisposition for PD and intestinal disease; variations in the LRRK2 and NOD2 genes are associated with both PD 70, 71 and Crohn's disease. [72] [73] [74] Another possibility is that the chronic inflammatory responses involved in GI diseases promote neuroinflammation and PD-associated neurodegeneration, a concept that is beginning to be tested in animal models. 7, 19 Enteric inflammation and other changes in the GI environment in PD could also contribute to disruption of intestinal immune tolerance and trigger clinical intestinal disease.
This study provides evidence that classic inflammatory processes are overly active in the intestine in PD patients and do not arise only in advanced disease. These could promote systemic and neuroinflammation and, ultimately, parkinsonian neurodegeneration. Because the immune mediators found to be elevated in PD patients would be produced in response to diverse insults, their specificity as biomarkers for PD is limited. Prospective studies would also be needed to determine when these indicators of GI inflammation appear in relation to motor symptoms. However, in combination with key pieces of patient information, it is possible that levels of select immune factors in stool could enable identification of individuals at risk for development of PD. Understanding the connections between intestinal inflammation and systemic and neuroinflammation may yield new insights into the mechanisms of PD pathogenesis and guide future investigations into immunomodulatory therapy that could potentially slow progression of the disease.
